Shaker Investments LLC OH Acquires New Position in Insulet Co. (NASDAQ:PODD)

Shaker Investments LLC OH acquired a new stake in Insulet Co. (NASDAQ:PODD) in the third quarter, Holdings Channel reports. The firm acquired 11,012 shares of the medical instruments supplier’s stock, valued at approximately $2,563,000.

Other institutional investors have also recently made changes to their positions in the company. Wedmont Private Capital raised its position in Insulet by 3.5% in the 3rd quarter. Wedmont Private Capital now owns 1,433 shares of the medical instruments supplier’s stock valued at $326,000 after purchasing an additional 48 shares during the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd raised its position in Insulet by 1.1% in the 2nd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 6,265 shares of the medical instruments supplier’s stock valued at $1,264,000 after purchasing an additional 66 shares during the last quarter. UMB Bank n.a. raised its position in Insulet by 81.0% in the 2nd quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier’s stock valued at $37,000 after purchasing an additional 81 shares during the last quarter. Moody National Bank Trust Division raised its position in Insulet by 2.6% in the 1st quarter. Moody National Bank Trust Division now owns 3,439 shares of the medical instruments supplier’s stock valued at $589,000 after purchasing an additional 87 shares during the last quarter. Finally, Motley Fool Asset Management LLC raised its position in Insulet by 7.1% in the 1st quarter. Motley Fool Asset Management LLC now owns 1,397 shares of the medical instruments supplier’s stock valued at $239,000 after purchasing an additional 93 shares during the last quarter.

Insulet Stock Performance

NASDAQ:PODD opened at $233.10 on Friday. The company has a quick ratio of 2.71, a current ratio of 3.60 and a debt-to-equity ratio of 1.36. Insulet Co. has a fifty-two week low of $125.82 and a fifty-two week high of $243.98. The stock has a market cap of $16.34 billion, a PE ratio of 42.38, a price-to-earnings-growth ratio of 4.34 and a beta of 1.21. The firm’s fifty day simple moving average is $214.20 and its 200-day simple moving average is $194.85.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Thursday, August 8th. The medical instruments supplier reported $0.55 earnings per share for the quarter, missing analysts’ consensus estimates of $0.56 by ($0.01). Insulet had a return on equity of 30.73% and a net margin of 21.11%. The company had revenue of $488.50 million for the quarter, compared to analyst estimates of $488.00 million. During the same period last year, the company earned $0.38 earnings per share. The business’s revenue for the quarter was up 23.2% compared to the same quarter last year. Analysts expect that Insulet Co. will post 3.04 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently commented on PODD shares. Piper Sandler upped their price target on shares of Insulet from $230.00 to $285.00 and gave the company an “overweight” rating in a research report on Tuesday, September 17th. Barclays boosted their price objective on shares of Insulet from $200.00 to $220.00 and gave the company an “equal weight” rating in a research note on Monday, August 12th. UBS Group boosted their price objective on shares of Insulet from $211.00 to $223.00 and gave the company a “neutral” rating in a research note on Friday, August 9th. Canaccord Genuity Group boosted their price objective on shares of Insulet from $236.00 to $269.00 and gave the company a “buy” rating in a research note on Wednesday, September 25th. Finally, BTIG Research dropped their price objective on shares of Insulet from $270.00 to $250.00 and set a “buy” rating on the stock in a research note on Friday, August 9th. Three research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $234.60.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.